Major Public-Private Collaboration in the Theranostics Market in Kansas
Published: 11 Mar 2026
Author: Precedence Research
The University of Kansas Health System, the University of Kansas Medical Center, Children’s Mercy, and Bold Advanced Medical Future (BAMF) Health announced a significant public-private partnership aimed at creating a fully integrated theranostics platform in Kansas City, catering to both adult and pediatric patients. Theranostics consists of a combination of diagnostic imaging with targeted therapy, utilizing the same molecular target most frequently radiopharmaceuticals in oncology, which enables clinicians to accurately identify, treat, and monitor cancer.
Major Features of Collaboration for Next-Generation Radiopharmaceutical Therapy
This initiative will consolidate molecular imaging, radioligand clinical trials, and radiopharmaceutical manufacturing into a unified and coordinated treatment facility. By integrating research, production, and care delivery within one facility, the partnership aspires to streamline development timelines, expedite trial enrollment, and enhance access to next-generation precision oncology treatments.
According to Precedence Research, the Theranostics Market size accounted for USD 10.29 billion in 2025 and is predicted to increase from USD 11.50 billion in 2026 to approximately USD 31.38 billion by 2035, expanding at a CAGR of 11.80% from 2026 to 2035 due to increasing prevalence of cancer and chronic diseases and advancement in radiopharmaceuticals.
A notable aspect of this collaboration is the incorporation of pediatric theranostics through Children’s Mercy. The majority of theranostics programs worldwide primarily focus on adult oncology, resulting in limited infrastructure for pediatric care. By integrating pediatric capabilities, the platform broadens its clinical reach and positions Kansas City as a comprehensive center for theranostics innovation across various age groups.
A new era for precision medicine at KU Medical Center
Leaders from the involved institutions highlighted that this model facilitates the swift implementation of advanced radiopharmaceutical trials that arise from research conducted at KU Medical Center. By merging academic research strengths with the production and operational capabilities of the private sector, the platform aims to diminish fragmentation and expedite the transition from scientific discovery to patient treatment. Ultimately, the Kansas City collaboration endeavors to establish a regional center of excellence in precision medicine while enhancing access to advanced cancer care for both adult and pediatric populations.
A recent report by Precedence Research highlights that the Theranostics market is benefiting from rising R&D investments, advanced molecular diagnostic technologies, and the rapid growth of personalized medicine and targeted therapies.